Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Brii Bio Approved to Launch Combination COVID-19 Therapy in China
Beijing Brii Biosciences (HK: 2137) reported
Brii has announced it would allocate an additional $100 million for global regulatory filings and commercialization of the therapy.
In the trial, there were no deaths over the 28 days of the follow-up in subjects who received the treatment versus nine in the placebo arm. The results were surprisingly similar in two groups of the active cohort: patients who received the therapy in up to five days after showing symptoms and patients who were treated six to ten days after becoming symptomatic.
Brii's drug was developed in partnership with the 3rd People’s
Brii Bio Greater China president and general manager Rogers Luo said: “This accomplishment is a testament to our steadfast commitment to accelerating innovation in infectious diseases and our ability to fulfill global unmet needs with speed, scientific rigor and impressive results."
He continued, "As a startup multi-national biotech company co-located in both China and the US, we are working to advance access to this treatment for a broad range of Covid-19 patients in China while also scaling its effort to match the need for Covid-19 treatment options to combat the pandemic.”
Brii is a China-US company that is developing therapies for infectious diseases such as hepatitis B virus (HBV), human immunodeficiency virus (HIV), multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, along with other conditions that include central nervous system (CNS) diseases.
See our other articles on Brii Bio.